
==== Front
Mol Psychiatry
Mol Psychiatry
Molecular Psychiatry
1359-4184
1476-5578
Nature Publishing Group UK London

38503923
2445
10.1038/s41380-024-02445-4
Perspective
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes
http://orcid.org/0000-0003-3698-0744
Vinkers Christiaan H. c.vinkers@amsterdamumc.nl

123
http://orcid.org/0000-0002-1662-7436
Kupka Ralph W. 4
Penninx Brenda W. 4
http://orcid.org/0000-0001-6072-0358
Ruhé Henricus G. 56
van Gaalen Jakob M. 34
van Haaren Paul C. F. 56
Schellekens Arnt F. A. 567
http://orcid.org/0000-0002-3878-3659
Jauhar Sameer 8
http://orcid.org/0000-0003-1622-0350
Ramos-Quiroga Josep A. 9101112
http://orcid.org/0000-0002-0548-0053
Vieta Eduard 13
Tiihonen Jari 14151617
Veldman Stijn E. 56718
Veling Wim 19
Vis Roeland 20
de Wit Laura E. 21
http://orcid.org/0000-0002-6439-2774
Luykx Jurjen J. 3422
1 https://ror.org/008xxew50 grid.12380.38 0000 0004 1754 9227 Department of Psychiatry and Anatomy & Neurosciences, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
2 grid.484519.5 Amsterdam Public Health, Mental Health Program and Amsterdam Neuroscience, Mood, Anxiety, Psychosis, Sleep & Stress Program, Amsterdam, The Netherlands
3 grid.420193.d 0000 0004 0546 0540 GGZ inGeest Mental Health Care, Amsterdam, The Netherlands
4 grid.12380.38 0000 0004 1754 9227 Department of Psychiatry, Amsterdam Neuroscience and Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
5 grid.5590.9 0000000122931605 Department of Psychiatry, Radboudumc, Radboud University, Nijmegen, The Netherlands
6 https://ror.org/016xsfp80 grid.5590.9 0000 0001 2293 1605 Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, The Netherlands
7 https://ror.org/01ydthg97 grid.491352.8 Nijmegen Institute for Scientist Practitioners in Addiction (NISPA), Nijmegen, The Netherlands
8 grid.13097.3c 0000 0001 2322 6764 Centre for Affective Disorders, Psychological Medicine, IoPPN, King’s College, London, UK
9 https://ror.org/03ba28x55 grid.411083.f 0000 0001 0675 8654 Department of Mental Health, Hospital Universitari Vall d’Hebron, Barcelona, Catalonia, Spain
10 https://ror.org/01d5vx451 grid.430994.3 0000 0004 1763 0287 Group of Psychiatry, Mental Health and Addictions, Vall d’Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain
11 grid.469673.9 0000 0004 5901 7501 Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain
12 https://ror.org/052g8jq94 grid.7080.f 0000 0001 2296 0625 Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain
13 https://ror.org/021018s57 grid.5841.8 0000 0004 1937 0247 Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
14 grid.9668.1 0000 0001 0726 2490 Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland
15 https://ror.org/056d84691 grid.4714.6 0000 0004 1937 0626 Department of Clinical Neuroscience, Karolinska Institutet, 11364 Stockholm, Sweden
16 Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden
17 https://ror.org/040af2s02 grid.7737.4 0000 0004 0410 2071 Neuroscience Center, University of Helsinki, Helsinki, Finland
18 Novadic-Kentron Addiction Care, Vught, The Netherlands
19 grid.4494.d 0000 0000 9558 4598 Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
20 https://ror.org/01jvpb595 grid.415960.f 0000 0004 0622 1269 Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands
21 https://ror.org/01jvpb595 grid.415960.f 0000 0004 0622 1269 Department of Psychiatry, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands
22 https://ror.org/02d9ce178 grid.412966.e 0000 0004 0480 1382 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands
19 3 2024
19 3 2024
2024
29 8 25752586
25 8 2023
22 12 2023
22 1 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Pharmacotherapy is an effective treatment modality across psychiatric disorders. Nevertheless, many patients discontinue their medication at some point. Evidence-based guidance for patients, clinicians, and policymakers on rational discontinuation strategies is vital to enable the best, personalized treatment for any given patient. Nonetheless, there is a scarcity of guidelines on discontinuation strategies. In this perspective, we therefore summarize and critically appraise the evidence on discontinuation of six major psychotropic medication classes: antidepressants, antipsychotics, benzodiazepines, mood stabilizers, opioids, and stimulants. For each medication class, a wide range of topics pertaining to each of the following questions are discussed: (1) Who can discontinue (e.g., what are risk factors for relapse?); (2) When to discontinue (e.g., after 1 year or several years of antidepressant use?); and (3) How to discontinue (e.g., what’s the efficacy of dose reduction compared to full cessation and interventions to mitigate relapse risk?). We thus highlight how comparing the evidence across medication classes can identify knowledge gaps, which may pave the way for more integrated research on discontinuation.

Subject terms

Addiction
ADHD
Bipolar disorder
Depression
Schizophrenia
JARQ was on the speakers’ bureau and/or acted as consultant for Biogen, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubió.EV has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB-Biotics, Abbott, Abbvie, Aimentia, Angelini, Biogen, Biohaven, Boehringer Ingelheim, Casen-Recordati, Celon, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo Smith-Kline, Idorsia, Janssen, Lundbeck, Novartis, Organon, Otsuka, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viatris.issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Clinical guidelines generally recommend prolonged pharmacological treatment following symptomatic remission, for example for antidepressants [1, 2] and antipsychotics [3], even though the minimal duration of continuation is often unspecified or variable [4, 5]. Although prolonged medication use can be effective, most patients discontinue their medication at some point, sometimes due to poor insight, but also because of symptomatic remission, lack of effectiveness, adverse events, or a perceived negative impact on functioning [6, 7]. However, patients and physicians are also concerned about episode recurrence and possible discontinuation symptoms (DS) [8, 9]. Given the frequency of discontinuation in clinical practice and the possible consequences, it is essential to have evidence-based clinical information on rational discontinuation strategies to guide patients, clinicians and policymakers.

In psychiatry, discontinuing medication is relevant for all major medication classes, i.e., antidepressants, antipsychotics, benzodiazepines, mood stabilizers, stimulants, and opioids. This may either involve complete discontinuation (stopping) or dose reduction strategies (staying on medication at a lower dose, sometimes below the minimally effective dose) [10]. Although answers to discontinuation topics may differ between medication classes, there may also be similarities. Therefore, comparing and integrating evidence can help to establish similarities and differences regarding discontinuation. Summarizing existing discontinuation knowledge can further help provide answers for patients and physicians and optimize discontinuation care.

Here, we provide an overview of the current evidence on discontinuation for all major medication classes used in psychiatry. For an overview of the pharmacological mechanisms hypothesized to subtend discontinuation symptoms, we refer to the Supplementary Text and Supplementary Fig. 1. Opioids are included due to their clinical relevance in discontinuation care (both illicit and prescription opioids) within psychiatry. We further discuss three major clinical questions for each medication class: (1) Who can discontinue with an acceptable risk of recurrence or discontinuation problems? (i.e., determinants of risk of DS, and relapse and recurrence risks following discontinuation); (2) When is the best time to discontinue following symptomatic remission?; and (3) How can medication best be discontinued to prevent recurrence or DS? (i.e., dose reduction strategies and effective discontinuation interventions). Finally, we compare similarities and differences across the medication classes.

Methods

The first and last authors revisited the current evidence on discontinuation across the six major medication classes used in psychiatry: antidepressants, antipsychotics, benzodiazepines, mood stabilizers, stimulants, and opioids. Experts from each medication class were invited to contribute for their respective field. All experts have made significant contributions to the literature in their respective field and most experts have multiple year of experience clinically guiding patients in discontinuing their psychotropic medication. Four consensus meetings were held between January 2021 and October 2021. During the consensus meetings, we defined three essential questions on discontinuation that we considered to be the most clinically relevant:Who can discontinue with an acceptable risk of recurrence or discontinuation problems? (i.e., determinants of risk of DS and relapse and recurrence risk following discontinuation);

When is the best time to discontinue following remission? (i.e., optimal timing of discontinuation); and

How can medication be most effectively discontinued to prevent recurrence or DS? (i.e., dose reduction strategies and discontinuation interventions).

For each psychotropic medication class, one or several expert(s) then conducted a targeted literature search and selected high-quality key research articles in the literature related to their area of expertise. Key search terms were: “antidepressants”, “antipsychotics”, “mood stabilizers”, “benzodiazepines”, “stimulants”, “opioids”, “discontinuation”, “tapering”, “discontinuation symptoms”, “discontinuation syndrome”, “withdrawal”, and “relapse”. After examining the literature on discontinuation, the expert panel identified commonalities between medication classes and reached consensus with regards to recommendations for clinical practice as well as future research avenues. Finally, the first and last authors critically revised and integrated these contributions into the current piece.

Discontinuation evidence across psychotropic medication classes

In the following section, we examine the three key clinical discontinuation questions (summarized in Table 1).Table 1 Summary of the major discontinuation evidence across medication classes.

	Relapse/recurrence rates after discontinuation vs. continuation (%)	DS chances per cessation attempt (%)	When to discontinue	Specific drugs with discontinuation problems	Discontinuation interventions	
Antidepressants	40% vs. 20% after 1 year [1, 2, 11–13]	27–86% [17]	For first-episode MDD: continue at least 4–6 months, longer after recurrent episodes [29, 31]	Paroxetine, duloxetine, and venlafaxine [17, 20, 156]	Preventive CBT [37, 38, 157]	
Antipsychotics	64% vs. 25% after 1 year [3]	37–70% [47]	First episode of psychosis (FEP): continue at least 1–2 years (with rapid full remission and few risk factors, discontinuation after 6 months may be considered) [53]	Clozapine	Relapse prevention plan with patient and family [67]	
Mood stabilizers	54% vs. 25% after 6 years [70]	Unknown	Continue maintenance treatment in already recurrent bipolar disorder for many years or even indefinitely [68]	Lithium; valproate	Relapse prevention plan with patient and family; frequent monitoring and continue monitoring for at least 1 year after discontinuation	
Benzodiazepines	Largely unknown beyond benzodiazepine use itself	59–78% [84, 85]	Discontinue benzodiazepines as soon as possible [94]	Short half-life benzodiazepines (e.g., lorazepam, temazepam) [89–91, 158]	Pharmacological: valproate, pregabaline [93], carbamazepine, TCAs [83, 93] Psychological: CBT, minor interventions [87, 100]	
Opioids	As analgesic: largely unknown

As agonist treatment for illicit opioid use: 71% relapse into illicit opioid use

	Unknown	As analgesic: discontinue opioids as soon as possible [132].

As agonist treatment: consider only if patient want to taper and risk of relapse into illicit opioid use is considered limited

	Opioids with a short half-life (e.g., morphine, oxycodone), and opioids with high mu-receptor affinity (e.g., fentanyl) [121]	Pharmacological:

Clonidine, anti-emetics, loperamide, lofexidine, guanfacine [137, 159]

Rotation to long-acting agent to facilitate gradual tapering.

Psychological:

CBT. Mindfulness [138]

	
Stimulants	60–70% with re-emergent ADHD symptoms [141, 142]	<5% [120, 143]	Evaluate the use of stimulants annually [145]	N/A	Benzodiazepines [150]	

Antidepressants

Who can discontinue?

Relapse rates after discontinuation

Continuing antidepressants in patients with major depressive disorder (MDD) who responded to acute treatment halves the relapse risk compared to placebo (from 40 to 20%), in both specialized and primary care [1, 2, 11–14]. The most recent meta-analysis on this topic found that the number needed to treat (NNT) was 6, favouring continuation of antidepressants [15]. A landmark study pointed in the same direction in the context of primary care [16]. An important limitation of double-blind placebo-controlled discontinuation studies is their relatively short follow-up period (study duration averaging 40 weeks) and often rapid or abrupt antidepressant discontinuation, although the absolute relapse risk gradually decreases over time in discontinued patients [2, 15].

Discontinuation symptoms (DS)

DS of antidepressants include a range of somatic (e.g., nausea, dizziness) and psychological (e.g., irritability, low mood) symptoms [8], and are summarized using the FINISH acronym, which stands for Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation). DS in SSRIs were found to be higher in both surveys of selected populations and open-label studies [17, 18] (55%), than in double-blind studies (30%) [19], possibly due to smaller nocebo effects in double-blind studies and selection bias in surveys. DS especially occur during treatment with SSRIs and SNRIs that have relatively short elimination half-lives (<24 h), such as paroxetine and venlafaxine [17, 20], though other mechanisms unrelated to elimination contribute as well. For example, paroxetine has strong affinity for the M1 receptor and also inhibits its own metabolism (just like fluvoxamine and fluoxetine) [21]. Abrupt discontinuation leads to higher DS incidence rates (35–100%) compared to tapering over several weeks (42–56%) for paroxetine [17]. Conversely, fluoxetine has an elimination half-life of around 5 days (active metabolite 4–16 days), and is generally associated with fewer DS [22]. It is hypothesized that most DS coincide with the largest reductions in serotonin transporter (SERT) occupancy, which particularly occur at lower doses [8, 23, 24]. DS generally quickly resolve after dose increases or reinstatement of the antidepressant, which can aid in distinguishing DS from relapse [8].

Risk factors for relapse or DS following discontinuation

To our knowledge, based on a systematic review, no consistent empirical evidence links patient characteristics to predicting DS, including residual symptoms, number of prior episodes, and duration of antidepressant use [25]. Length of antidepressant use has been suggested to be a risk factor for some antidepressants, though the data are inconsistent [1]. Possible predictors of relapse following discontinuation are effort-reward decision time and cognitive reactivity, the latter being the most consistent predictor independent of residual symptoms [26–28]. However, these predictors have not been firmly established.

When to discontinue?

Most guidelines recommend to continue antidepressants for at least 4–6 months after successful acute-phase therapy in patients with first-episode MDD to prevent relapse, and longer periods after recurrent MDD [29–31]. Nevertheless, there is little evidence supporting a minimum duration of antidepressant treatment after stable remission. Patients with recurrent MDD should stay on treatment longer and sometimes indefinitely [16].

How to discontinue?

Discontinuation strategies

Consensus supports slow discontinuation of antidepressants, but few randomized studies have compared discontinuation strategies. Most studies employ a rather rapid 2-week tapering period with at most two steps [32–34]. Compared to abrupt discontinuation, 1–3-week tapering schedules lower DS frequency [32–34]. Although hyperbolic tapering, which involves decreasing relative dose reductions over time (Supplementary Text), is supported by expert opinion, it lacks evidence [8, 35]. Given the heterogeneity of DS between antidepressants and individual patient variation, general advice would be to slowly taper in those taking antidepressants for longer periods of time (e.g., years), and antidepressants with higher DS risk.

Dose reduction

A meta-analysis of five randomized trials found that dose reductions of phenelzine, maprotiline, imipramine, amineptine, and paroxetine increased the risk of MDD relapse by 62% relative to the group randomized to unchanged continuation [36].

Discontinuation interventions

A meta-analysis of four randomized controlled trials found no significant difference in time to depression relapse between patients receiving psychological interventions (e.g., cognitive behavioral therapy) during or after antidepressant tapering, compared to those who continued with antidepressant maintenance therapy only [37]. Another meta-analysis of 12 RCTs showed that MDD patients receiving psychotherapy during antidepressant treatment or tapering had a lower rate of relapse compared to those receiving active controls (antidepressant treatment) or treatment as usual [38]. In conclusion, a (preventive) psychotherapy is as effective as antidepressant maintenance.

Antipsychotics

Who can discontinue

Relapse rates after discontinuation

Within 18 months after treatment initiation, 74% of patients with schizophrenia discontinue because of adverse events or insufficient efficacy [39]. A comprehensive network meta-analysis of RCTs found that all continuation strategies outperformed discontinuation, with large risk reductions for continuing at standard dose (RR = 0.37; NNT = 3.2) and switching antipsychotics (RR = 0.47; NNT = 3.6) [40]. Dose reduction was moderately effective in relapse prevention (RR = 0.68; NNT 6.3) but was outperformed by continuation and switching strategies [40]. Doses below recommended levels were also associated with relapse in other studies (in first and multi-episode schizophrenia), possibly due to insufficient D2 receptor occupancy [41, 42]. Moreover, risk of poor clinical outcomes doubles in schizophrenia patients discontinuing antipsychotics at 10-year follow up relative to those continuing antipsychotics [43]. This is supported by European and Asian registry observational and cohort studies, which found lower rehospitalization rates in patients continuing antipsychotics compared to discontinuation [44]. It is also supported by observed reductions in relapse rates and mortality in patients on long-acting antipsychotics as compared to those taking oral antipsychotics [45, 46].

Discontinuation symptoms (DS)

Antipsychotic-associated DS can be somatic (e.g., nausea, sweating), motor (e.g., restlessness), and psychological (e.g., irritability) in nature [47]. Hyperkinesia may also occur upon withdrawal and can last for months [48]. A systematic review of five studies (of mediocre quality) found a pooled frequency of DS of 53%, while abrupt discontinuation resulted in DS in 37–70% of patients (Table 1), with nocebo effects potentially playing a role [47].

Risk factors for relapse following discontinuation

Established risk factors for relapse after discontinuation or dose reduction include a diagnosis of schizophrenia (as compared to other psychotic disorders), long illness duration, poor pre-morbid functioning, no receipt of psychosocial intervention programs during discontinuation, shorter follow-up and in-hospital care [49–51]. Increased prolactin concentration, recurring hospitalizations, higher score on the Clinical Global Impression (CGI) severity scale, smoking, oral antipsychotic treatment (compared to long-acting injectables) and smoking have also been identified as predictors for relapse after discontinuation [52].

When to discontinue

Even though guidelines differ in their recommendations, several of them advise antipsychotic continuation up to 1–2 years after a first episode of psychosis (FEP) and life-long maintenance treatment after multiple psychotic episodes [53]. For those with a FEP, quick recovery and few poor prognostic factors, discontinuation may be considered after 6 months of remission. Relapse risk increases with longer illness duration and time since discontinuation [43, 54, 55]. We therefore emphasize the need for careful shared decision-making on discontinuing antipsychotics for patients who have been using them for longer time periods.

How to discontinue

Discontinuation strategies

For antipsychotic discontinuation, no evidence exists that gradual tapering decreases the risk of DS, although some recommend gradual and slowly (in months, possibly hyperbolic) tapering over quicker or abrupt discontinuation (Supplementary Text) [51, 56]. Tapered discontinuation (compared to abrupt discontinuation) may reduce the risk of adverse somatic events after full discontinuation [57], although the minimum dose threshold appears to have more relevance [51].

Dose reduction

To our knowledge, no published trials have compared dose reduction with complete discontinuation. A meta-analysis found that dose reduction doubles relapse risk relative to dose maintenance, particularly below 200 mg/day chlorpromazine equivalent or 2.5 mg risperidone equivalent, highlighting the importance of the extent of dose reduction [58, 59]. The one trial at the time of writing that had compared antipsychotic dose reduction with maintenance strategies was conducted in people with recurrent psychotic disorders and FEP [10]. It compared maintenance treatment with gradual, monitored, reduction of antipsychotics over several months (median dose reduction at any point 67% in the reduction group and 0% in the maintenance group). The results indicate that social functioning after 2 years is equal between groups, but that the risk of severe relapse is higher in the dose reduction than the maintenance group [10]. In contrast, observational data hint at possible functional improvements in functioning after antipsychotic dose reduction in similar patient populations [60, 61], but the possibility of confounding by indication precludes definitive conclusions from such data. New trials are underway to compare dose reduction or drug discontinuation with continuation strategies [62, 63], including guided dose reduction to establish the minimum effective dose [64]. Besides dose reduction studies, intermittent dosing strategies have also been proposed, with either regular gaps in dosing (from alternate days to several weeks) [65], or only initiating antipsychotics when psychotic symptoms emerge, with no antipsychotic use between psychotic episodes. While the first strategy has shown some merits if drug-free days are few, the second strategy increased relapse risk and rehospitalization [66], limiting the current role of intermittent dosing strategies for antipsychotics.

Discontinuation interventions

No interventions to mitigate relapse risks in those discontinuing antipsychotics have been described. In clinical practice, patients tapering antipsychotics are closely monitored, family members may be involved, and psychosocial interventions may be considered [67].

Mood stabilizers

Who can discontinue?

Relapse rates after discontinuation

General: the question whether to continue or stop a mood stabilizer (lithium, valproate, lamotrigine, and carbamazepine) is relevant in long-term prophylactic (maintenance) treatment of bipolar disorder [68]. Patients with multiple recurrences are obvious candidates for long-term maintenance pharmacotherapy, but convincing evidence for this strategy is scarce [69]. Sustained (e.g., ≥10 years) maintenance therapy without relapses can hint that treatment may be no longer needed, but can also indicate treatment effectiveness, given the general assumption that bipolar disorder is a lifelong illness with a high risk of recurrence [68]. Given the highly heterogeneous course of bipolar disorder, decisions about whether or not to discontinue maintenance treatment require a thorough evaluation of illness course before and during treatment and assessment of risk factors for recurrence in each individual patient, as well as patients previous experiences with stopping mood stabilizers [68].

Lithium: few studies have reported follow-up after discontinuation vs. discontinuation of maintenance treatment. One observational study found that continuous lithium use reduced relapse risk by half compared to discontinuation during 6 year follow-up [70]. It is important to note that lithium discontinuation, particularly abrupt discontinuation, can lead to increased suicidality [71].

Valproate/carbamazepine/lamotrigine: a meta-analysis on lithium, lamotrigine, and second-generation antipsychotics (SGA’s) found a 61% relative risk reduction after 6 months in continuation compared to discontinuation groups [72].

Antipsychotics: although SGA’s are not mood stabilizers in the strict sense, several SGA’s have been recommended for maintenance treatment in bipolar disorder as monotherapy or combined with a mood stabilizer: quetiapine, asenapine, aripiprazole, olanzapine, risperidone, paliperidone, and lurasidone [72].

Discontinuation symptoms (DS)

Lithium: discontinuation of lithium may lead to irritability, anxiety, restlessness, vertigo, dizziness, and lightheadedness, particularly in the first week. Symptoms are generally mild and self-limiting [48, 73]. Abruptly or rapidly stopping lithium (within 2 weeks) can lead to “rebound” manic and depressive episodes [74]. There is no strong evidence that lithium is less effective when discontinued and restarted, compared to continuous treatment, a phenomenon that has been seen in anecdotal case reports and in about 15% of patients across seven published cohort studies [75].

Valproate/carbamazepine/lamotrigine: for carbamazepine, valproate, and lamotrigine, discontinuation phenomena include anxiety, agitation, irritability, lack of energy, depression, insomnia, depersonalization, and impaired concentration and memory [48].

Antipsychotics: SGA’s have been addressed in the section on antipsychotics above.

Risk factors for relapse following discontinuation

In bipolar disorder, young age of onset, psychotic features, numerous previous episodes, rapid cycling, comorbid anxiety, comorbid substance use, and persistent subthreshold symptoms are risk factors for recurrence, even during maintenance treatment [76]. These factors likely increase the risk of relapse following discontinuation, although direct evidence is lacking.

When to discontinue?

Most guidelines recommend that mood stabilizers for acute manic or depressive episodes be continued at least for several months after symptomatic remission (i.e., during the continuation treatment phase following the acute treatment and preceding maintenance treatment) [77], but evidence is scarce. However, in most patients with bipolar disorder it is recommended that a mood stabilizer should be continued for long-term maintenance treatment to prevent recurrences and improve inter-episodic functioning [68, 76].

How to discontinue?

Discontinuation strategies

Lithium: gradual discontinuation of lithium (at least over a month) reduces risk of DS and early recurrence relative to rapid discontinuation [74]. In clinical practice, lithium and other mood stabilizers are often tapered hyperbolically (Supplementary Text) [78]. If lithium needs to be discontinued because of inefficacy or severe side effects, it may be replaced with another mood stabilizer or SGA [79].

Valproate/carbamazepine/lamotrigine: it is unclear whether this also applies to other mood stabilizers [48].

Dose reduction

Lithium: for lithium, recommended effective doses for the prevention of manic and depressive episodes result in blood plasma levels of 0.6–0.8 mmol/l, or, in some cases, 0.4–0.6 mmol/l [80]. Dose reductions below these levels may diminish effectiveness.

Valproate/carbamazepine/lamotrigine: minimally effective blood levels are less robustly established than for lithium: 50 mg/l for valproate, 4 mg/l for carbamazepine, and 3 mg/l for lamotrigine.

Discontinuation interventions

There are no known interventions to reduce relapse risk or DS during or after mood stabilizer discontinuation. Closely monitoring mood symptoms during discontinuation of mood stabilizers is recommended, for at least 1 year [78].

Benzodiazepines

Who can discontinue?

Relapse rates after discontinuation

Relapse rates for benzodiazepines are generally intricate to ascertain given the diversity of symptoms for which benzodiazepines are prescribed. Nevertheless, the majority of patients succeed in discontinuing benzodiazepines, as shown by systematic reviews and meta-analyses that found an average 1-year discontinuation success rate of 55–64% [81–83].

Discontinuation symptoms (DS)

Most patients discontinuing benzodiazepines experience some degree of DS (59–78%) [84, 85]. Physical DS of benzodiazepine discontinuation include muscle tension, weakness, spasms, pain, and influenza-like symptoms (sweating and shivering). Psychological DS include anxiety and panic attacks, restlessness, agitation, depression, mood swings, concentration difficulties, and sleep disturbances [86, 87]. In rare instances, rapid discontinuation may induce more severe DS, including seizures and psychotic symptoms [88]. DS may emerge or worsen weeks after discontinuation, with highest risks in short elimination half-life benzodiazepines (temazepam and lorazepam) [89–91].

Risk factors for relapse following discontinuation

Patients often want to stop after long-term benzodiazepine use, but face barriers such as dependence and misuse, reliance on benzodiazepines for comfort, and anticipation of sleep problems [92]. Intrinsic motivation and sufficient time to consider the benefits of discontinuation can help [92].

When to discontinue?

For most patients, adverse events of long-term benzodiazepine use (e.g., increased fall risk, sleepiness and cognitive impairment) do not outweigh the benefits [93]. For the sedative and anticonvulsant actions of benzodiazepines, discontinuation should commence before tolerance develops (i.e., first weeks of use) [94]. There is no evidence suggesting that discontinuation is easier after short-term use than long-term use. Regarding the anxiolytic and amnesic effects of benzodiazepines, there is no evidence that tolerance develops. The risk/benefit ratio of continued use should be discussed at least annually and discontinuation advised where possible.

How to discontinue?

Discontinuation strategies

Benzodiazepines should be gradually discontinued to prevent seizures and severe DS after more than 3 months of use [78]. Even after chronic use, discontinuation over a period of less than 6 months is feasible and appropriate [95]. Gradual dose reduction reduces DS intensity and improves discontinuation success [95]. However, no RCTs have compared different dose reduction methods. UK guidelines pragmatically suggest a reduction of about 12.5% of the daily dose every 2 weeks [96]. In clinical practice, a weekly reduction of 25% for the first 75% of the dose, followed by hyperbolic tapering or steps of 12.5% for the final 25% of the dose is often used [97]. There is no evidence for week-on week-off (pulse) dosing [98]. Switching to a long-acting benzodiazepine before discontinuation may be preferable for some patients, particularly when discontinuation attempts have failed, or with high doses (over 30 mg diazepam equivalent) [90, 95, 99]

Dose reduction

No evidence comparing dose reduction to discontinuation exists. Long-term use of benzodiazepines is generally not recommended and complete discontinuation should be attempted.

Discontinuation interventions

Cognitive behavioral therapy add-on results in little added value over solely gradual dose reduction in the long run (>6 months post-intervention) [87, 100]. Multifaceted deprescribing interventions are effective in reducing benzodiazepine use [101]. While motivational interviewing may be used, there is insufficient evidence for its standard application [87]. Gradual dose reduction combined with a brief or “minimal” intervention (personalized letter, self-help information) in primary care is superior to routine care alone [102–104]. Generally, interventions focused on patient self-awareness and education up discontinuation successes [92]. Valproic acid, carbamazepine and tricyclic antidepressants may help with benzodiazepine discontinuation, albeit with low quality evidence [83, 93]. The use of flumazenil for benzodiazepine discontinuation remains experimental [105, 106].

Opioids

Who can discontinue?

Relapse rates after discontinuation

Opioids are commonly prescribed for two indications: analgesic indications and agonist treatment in patients with illicit opioid use. As an analgesic, opioids have a place in acute and cancer-related pain. However, continued long-term use for chronic non-cancer pain may induce adverse events, such as elevated pain, mood disorders and reduced quality of life, without clear benefits as an analgesic [107–111]. In these cases, opioid discontinuation should be initiated as early as possible as nearly 5% of patients develop an opioid use disorder [112]. Patients with chronic non-cancer pain and an opioid use disorder discontinuing their opioids have a relapse rate of 23% after 1 year [113, 114]. In patients on opioid agonist treatment (methadone or buprenorphine), the aim is to reduce opioid-related harm [115]. These patients generally had several previous failed attempts to stop illicit opioid use. Patients with illicit opioid use disorder who use agonist treatment have a relapse rate of 71% within 1 month after discontinuation of agonist treatment [113, 114]. Treatment goals for these patients should be more toward harm reduction with opioid agonist therapy (i.e., methadone or buprenorphine) instead of tapering. Only in a subset of individuals who have a wish to taper or discontinue their agonist treatment, and have improved psychological or social conditions, such as improvement on co-occurring mental disorders or housing situations, tapering or discontinuation can be considered [115].

Discontinuation symptoms (DS)

Opioid discontinuation in patients with chronic pain reduces pain severity and improves quality of life [116]. Increased pain and craving can occur in some patients in short term, particularly at higher doses [117]. In patients on agonist treatment, discontinuation of agonist treatment has been associated with increased craving levels, and reduced quality of life. Discontinuation of prescription opioids is usually accompanied by DS after more than 3 weeks of use [116, 118, 119]. Typical opioid DS include dysphoria, anxiety, agitation, nausea, muscle ache, rhinorrhea, sweating, diarrhea, yawning, fever, and insomnia [120]. Higher opioid doses and long-term use result in more severe DS, while long-acting opioids (methadone or buprenorphine) cause less severe DS [121]. Among patients with opioid use disorders, acute discontinuation or rapid tapering of opioids may lead to withdrawal that requires medical care [122]. In individuals discontinuing opioids after long-term use for chronic pain, suicidal ideation and self-directed violence may occur [123124]. Overdose-related morbidity is more likely in the first month after discontinuation, due to decreased tolerance to original doses following relapse [125]. Opioid discontinuation may result in illicit opioid use, including heroin and illegally manufactured fentanyl [126].

Risk factors for relapse following discontinuation

Individuals dissatisfied with their opioid use and those not experiencing the desired analgesic effect are more likely to discontinue opioids successfully [118, 127]. Young age, low doses, short duration of use, good socio-economic context, and a negative history of psychiatric illness are positively associated with successful opioid discontinuation [118, 127–130]. Conversely, adequate depression treatment may increase the incidence of opioid use cessation in patients with chronic pain [131].

When to discontinue?

Opioids prescribed as analgesics should be discontinued before tolerance develops as long-term use is not indicated for chronic (non-cancer related) pain [132]. The risk/benefit ratio of continued use should be discussed regularly and discontinuation advised when possible.

In patients on opioid agonis treatment, treatment effectiveness, and co-use of other drugs (including illicit opioids) should regularly assessed. In individuals who have a wish to taper or discontinue their agonist treatment, and have improved psychological or social conditions, such as improvement on co-occurring mental disorders or housing situations, tapering or discontinuation can be considered [115].

How to discontinue?

Discontinuation strategies

Patients on low-dose prescription opioids (<20 mg oral morphine equivalents) and/or for a short duration (<2–3 weeks) can generally discontinue without tapering [128]. In other patients, tapering is advised [128]. More rapid tapering generally results in more severe withdrawal and lower success rates [133, 134]. The advised rate of discontinuation in guidelines ranges between 10% per month and 50% per week of the initial dose, with slower tapers (i.e., 10% reduction per month) being more likely to be better tolerated [133, 134]. If rapid discontinuation of opioids is necessary for medical reasons, reduction strategies of up to 50% per week are possible [128]. Switching to long-acting opioids (usually 70% dose-equivalent) can be considered with high doses (>90 mg morphine equivalents) and/or prolonged opioid use (>3 months), but also in patients with prior failed discontinuation attempts. Long-acting opioids should be tapered to the lowest possible dose, and then discontinued [135, 136].

Dose reduction

Discontinuation should be the primary goal in patients using opioids for analgesic purposes. Nevertheless, in patients at high risk of relapse (high opioid doses, long-time use, either with or without opioid use disorder) [118, 128, 129], long-acting opioid agonist treatment (e.g., methadone or buprenorphine) can be considered [137]. In patients on agonist treatment, dose reduction strategies are recommended when adverse events develop, or in the event of pharmacokinetic changes, e.g., due to co-medication, successful treatment of hepatitis, or ageing.

Discontinuation interventions

Mindfulness and cognitive behavioral therapy in patients with opioid use disorder result in lower perceived pain and focus on analgesics [138]. Such strategies may facilitate discontinuation of opioids, although evidence is lacking. There is limited evidence for clonidine for agitation, shaking and muscle ache, anti-emetics for nausea, and loperamide for diarrhea. For insomnia, benzodiazepines should be given with caution in this patient group, due to their risk of developing sedative use disorder [137].

Stimulants

Who can discontinue?

Relapse rates after discontinuation

Patients with ADHD who continue stimulants have a better quality of life, less impulsive behavior and hyperactivity, compared to those who discontinue [139, 140]. The majority of patients who discontinue stimulants need to re-start treatment within 2 weeks due to worsening of ADHD symptoms REF. Nevertheless, ~30% of children with ADHD can discontinue their stimulants without worsening of ADHD symptoms at 3 months follow up [141, 142].

Discontinuation symptoms (DS)

DS are uncommon after discontinuation, although transient fatigue, insomnia (or hypersomnia), vivid dreaming, and irritability have been described [120, 143]. Transient motor symptoms may particularly occur with concomitant use of antipsychotics.

Risk factors for relapse following discontinuation

Re-emergence of ADHD symptoms is independent of age and sex, although adults may be at less risk compared to minors after stimulant discontinuation [139, 144]. There are no other reliable predictors for successful stimulant discontinuation.

When to discontinue?

Guidelines recommend to annually review patients taking prescription stimulants. During such evaluations, patients’ perspectives, risk-to-benefit ratios, and medication doses should be evaluated [145]. Prolonged treatment is recommended in adolescence, due to a high level of negative outcomes in ADHD patients during this age phase. The American Academy of Child and Adolescent Psychiatry suggests clinicians consider stimulant discontinuation in ADHD after a 1-year period without significant ADHD symptoms, dose adjustments, or symptom worsening during drug holidays [146].

How to discontinue?

Discontinuation strategies

Discontinuation of prescribed stimulants is considered safe, usually without tapering. In clinical practice, tapering stimulants is sometimes considered, while lacking evidence [139, 147].

Dose reduction

One RCT found that a 50% dose reduction results in significant worsening of ADHD symptoms [148]. At the risk of unwanted worsening drug adherence [149], drug-free “holidays” may have positive effects on ADHD symptoms and adverse events [139].

Discontinuation interventions

Guidelines on detoxification of non-prescribed stimulants support the use of supportive measures. Short-term (<2 weeks) use of benzodiazepines may reduce irritability and improve sleep [150].

Integration of evidence across medication classes

From the current evidence across medication classes in this perspective, we identified seven commonalities that are discussed below (see also Supplementary Text, Section 2 for more details). An important limitation that should be kept in mind is that the discontinuation studies at hand often have methodological shortcomings, including short follow up, as well as abrupt or very rapid discontinuation schedules [151]. There is thus a strong need for more robust evidence to guide evidence-based decision-making on psychotropic drug discontinuation in clinical practice.

Discontinuation symptoms are common but remain difficult to predict

First, discontinuation symptoms are common, particularly after abrupt or rapid cessation of medication, except in the case of stimulants. These symptoms generally dampen over time and seem less likely when discontinuation occurs gradually. In general, DS risk is higher for psychotropic drugs with shorter elimination half-lives, such as paroxetine, venlafaxine, clozapine, morphine, oxycodone, lorazepam, and temazepam (Table 1). Nevertheless, estimations of DS prevalence across medication groups are heterogeneous (see also Table 1). A challenge is that DS are often not measured at all, and, if measured, their operationalization varies (e.g., concerning questionnaires, cutoff values, and time points) [18]. Moreover, in many blinded studies, medication is abruptly stopped. Thus, current estimations of DS not only reflect the situation following abrupt or very quick cessation, but also include the influence of expectations and patients and clinicians’ experiences and may thus be subject to nocebo effects. Finally, it can be challenging to disentangle DS from relapse due to symptom overlap [8]. This may result in DS being misdiagnosed as relapse in discontinuation studies [22].

Do not discontinue medication too quickly

Second, it is clear that abrupt discontinuation is not only associated with DS, but also entails increased relapse risks. Nevertheless, the optimal period during which medication should be discontinued and the rate of dose reduction are unclear. Pragmatically, discontinuation over months is advisable, but evidence for these strategies is lacking. Gradual lowering of the dose is generally recommended for several reasons. First, relapse may be less severe if a patient is on a medium or low dose relative to discontinuation. Second, steady-state may be more readily re-achieved if relapse occurs while a patient is on a lower dose. Third, gradual tapering may be more comfortable for patients because of the decreased likelihood of DS. Gradual tapering is often possible using conventional dose regimens, and many patients can discontinue using these existing doses. Nevertheless, when discontinuation poses a greater challenge, a gradual decrease with low doses may be feasible. Another option that becomes apparent across medication classes is the possibility to switch to long-acting agents, e.g., diazepam, sustained-release buprenorphine and fluoxetine (although of the latter intervention only case reports are known). For some medications, e.g., opioids and antipsychotics, (demographic) variables have been associated with successful tapering, but given the lack of replicated findings these are not ready for translation into clinical practice.

Urgent need for more interventions to help patients successfully discontinue

Third, the literature on pharmacotherapeutic and psychological interventions to help patients start and finish tapering regiments is heterogeneous. For benzodiazepines, easy-to-use interventions, such as letters, are effective, but whether this extends to other medication classes is unknown. For preventive CBT, there is some evidence that it can help successfully discontinue antidepressants. More intervention studies are needed to assess whether time-intensive psychosocial interventions, CBT or simple interventions can help patients discontinue. For drugs that can lead to physical dependence (i.e., benzodiazepines and opioids), the need to discontinue is often relatively urgent and pressing.

Many patients can successfully discontinue

Fourth, while relapse risks increase after discontinuation (two-fold for antidepressants, stimulants and higher for antipsychotics), a (considerable) proportion of patients do not relapse. Conversely, a substantial proportion of patients still relapses while using medication. Therefore, the long-term perspective of discontinuation is that the risk-benefit ratio may shift for patients toward stopping their medication at some point, at least once. The weighing of risks vs. benefits related to discontinuation are personal and involve considerations about side effects, patient preferences, psychiatric history, and treatment efficacy. We believe that (dis)continuation should be periodically discussed with patients and family, and an emergency plan with relapse signs and subsequent advised actions can be helpful.

Chronic treatment with benzodiazepines and opioids should be discouraged

Fifth, discontinuing benzodiazepines and opioids is different from stopping antidepressants, mood stabilizers, or antipsychotics due to their potential for dependence after chronic use. The decision to discontinue should, in our opinion, be based on shared decision-making between patients and their families, physicians, and pharmacists. Shared decision-making can facilitate one to come up with the most viable strategy, which often includes considerations about relapse risk as well as other domains, such as quality of life and well-being.

Relapse is too narrow an outcome

Sixth, studies have predominantly focused on relapse risk, largely ignoring other outcomes relevant to patients, such as social functioning or subjective well-being. Moreover, there are varying definitions of relapse and remission both within and across different diagnostic entities, such as MDD, bipolar disorder, and schizophrenia. Therefore, even though phenotypes may be comparable, unique patterns and courses within a certain disorder necessitate uniform criteria for what constitutes relapse or remission. This heterogeneity of definitions hampers comparisons of relapse rates across disorders, and emphasize to include outcomes that are transdiagnostic and transcend relapse-based outcomes. Incorporating a transdiagnostic approach in future discontinuation studies, and including patient groups with conditions like schizoaffective disorder and bipolar depression, is crucial to broaden our understanding across various psychiatric disorders, highlighting the need for adaptive and individualized treatment protocols, regardless of specific diagnosis.

The need for shared decision making and integrated deprescribing

Shared decision-making is essential for the success of the discontinuation strategy, tailoring decisions to individual patient needs, abiding by informed consent procedures and empowering a patient’s autonomy, while at the same time carefully weighing in the harm/benefit ratio of discontinuation [152]. Moreover, the overall infrastructure of a county’s healthcare system is an important determinant of how discontinuing practices can be implemented. For instance, in a well-resourced healthcare system, there might be more opportunities for close monitoring, early intervention, and comprehensive support services, which can be pivotal in preventing relapse. This aspect is often under-discussed but is critical for understanding and improving treatment outcomes in mental health care. Indeed, rational deprescribing can benefit from interdisciplinary support and interdisciplinary collaboration, wherein physicians and pharmacists together discuss with patients to decide whether or not to discontinue [153].

Conclusion

Cross-pollination across medication classes has helped us to identify, catalog, and advance our knowledge on medication discontinuation in psychiatry. For clinicians it is important to have background knowledge about this topic to be able to advise on the safest strategies for treatment discontinuation for patients considering discontinuation [154]. There is already quite some evidence that can be applied to clinical practice where patients often have limited help in the discontinuation of their medication. At the same time, it is also clear that both the quantity and quality of discontinuation evidence is not only heterogeneous, but also quite limited [155]. Therefore, in Box 1, we have summarized several recommendations on how to further advance our knowledge about discontinuation in psychiatry. We believe research priorities should be drawn toward deprescribing in psychiatry, aiming to help patients and clinicians discontinue responsibly and jointly.

Box 1 Recommendations for future research to advance our knowledge about discontinuation of psychotropic medication Recommendations

From the current evidence across medication classes in this perspective, we signal several recommendations for future research:More double-blind placebo-controlled discontinuation studies are needed that compare different discontinuation strategies, including the efficacy of hyperbolic discontinuation strategies, for which there is currently limited evidence.

Experimental medicine studies, including molecular imaging studies, are necessary to examine the mechanisms of discontinuation, also regarding the putative hyperbolic discontinuation strategies.

The RCT is the most convincing, but not the only study design that can answer discontinuation questions. Cohort/case-control studies, qualitative studies on subjective experiences, single case study designs and real-world studies may all result in relevant insights.

There is an urgent need for more reliable predictors at the level of the individual patient or medication that related to relapse and DS. Therefore, across discontinuation studies, both intervention or clinical studies, consistent information should be collected on patient and medication characteristics (e.g., the number of past episodes, personality characteristics, and neurobiological correlates).

Extend outcomes beyond the narrow outcomes of relapse, and include (long-term) functional outcomes and well-being.

We should strive for discontinuation studies where patients are allowed with residual symptoms to enter, and not limit to one specific DSM diagnosis (e.g., MDD).

More clinical and real-world studies should compare dose reduction with complete discontinuation.

With regards to the (neuro)biological and psychological mechanisms of discontinuation symptoms, we recommend integrating placebo/nocebo effects, hyperbolic tapering strategies, and the role of expectations in future discontinuation studies.

Discontinuation symptoms should be measured consistently across studies. The DESS scale is a possible candidate for antidepressants, the OWS (opioid withdrawal scale) for opioids, and the BWSQ (benzodiazepine withdrawal scale) for benzodiazepines.

Supplementary information

Supplementary Text

Supplementary Figure 1

Supplementary Figure 1 Legend

Supplementary information

The online version contains supplementary material available at 10.1038/s41380-024-02445-4.

Author contributions

The authors confirm contribution to the paper as follows: study conceptualization and design: CV and JL; data collection: CV, RK, BP, HR, JG, PH, AS, SJ, JR, EV, JT, SV, WV, RV, LW, and JL; analysis and interpretation of results: CV, RK, HR, JG, PH, AS, SJ, JR, EV, JT, SV, WV, RV, LW, and JL; draft manuscript preparation: CV, RK, HR, JG, PH, AS, JT, SV, WV, RV, LW, and JL; draft review and editing: BP, SJ, JR, and EV. All authors reviewed the results and approved the final version of the manuscript.

Competing interests

CV received research funding from ZonMW, Hersenstichting. HR received research funding from ZonMW, Hersenstichting, an unrestricted educational grant from Janssen and speaking fees from Janssen, Prelum, Benecke and Lundbeck. CV and HR are PIs of the TEMPO RCT examining different discontinuation strategies. SJ has received honoraria for educational talks given for Lundbeck, Boehringer-Ingelheim, Janssen and Sunovion. He has consulted for LLA Pharmaceuticals on an antipsychotic and has sat as panel member for a Wellcome Trust funding panel and expert member for a NICE panel on tardive dyskinesia. He is a Council Member for the British Association for Psychopharmacology (unpaid). JT has participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to his employing institution. He has been a consultant to HLS Therapeutics, Janssen, Orion and WebMed Global and received lecture fees from Janssen and Otsuka. JR was on the speakers’ bureau and/or acted as consultant for Biogen, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen-Cilag, Shire, Oryzon, Roche, Psious, and Rubió. EV has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB-Biotics, Abbott, Abbvie, Aimentia, Angelini, Biogen, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo Smith-Kline, Idorsia, Janssen, Lundbeck, Novartis, Organon, Otsuka, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viatris. RV, LW, WV, AS, SV, JL, BP, JG, RK, and PH have no conflict of interests to declare.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Baldessarini RJ Lau WK Sim J Sum MY Sim K Duration of initial antidepressant treatment and subsequent relapse of major depression J Clin Psychopharmacol 2015 35 75 6 10.1097/JCP.0000000000000263 25502491
Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol. 2015;35:75–6.25502491
2. Geddes JR Carney SM Daview C Furukawa TA Kupfer DJ Frank E Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review Lancet 2003 361 9 10.1016/S0140-6736(03)12599-8
Geddes JR, Carney SM, Daview C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:9.
3. Leucht S Tardy M Komossa K Heres S Kissling W Salanti G Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis Lancet 2012 379 2063 71 10.1016/S0140-6736(12)60239-6 22560607
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.22560607
4. Cleare A Pariante CM Young AH Anderson IM Christmas D Cowen PJ Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines J Psychopharmacol 2015 29 459 525 10.1177/0269881115581093 25969470
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29:459–525.25969470
5. Kennedy SH Lam RW McIntyre RS Tourjman SV Bhat V Blier P Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments Can J Psychiatry 2016 61 540 60 10.1177/0706743716659417 27486148
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61:540–60.27486148
6. Ambresin G Palmer V Densley K Dowrick C Gilchrist G Gunn JM What factors influence long-term antidepressant use in primary care? Findings from the Australian diamond cohort study J Affect Disord 2015 176 125 32 10.1016/j.jad.2015.01.055 25704565
Ambresin G, Palmer V, Densley K, Dowrick C, Gilchrist G, Gunn JM. What factors influence long-term antidepressant use in primary care? Findings from the Australian diamond cohort study. J Affect Disord. 2015;176:125–32.25704565
7. Samalin L Belzeaux R Why does non-adherence to treatment remain a leading cause of relapse in patients with bipolar disorder? Eur Neuropsychopharmacol 2023 73 16 8 10.1016/j.euroneuro.2023.04.012 37119557
Samalin L, Belzeaux R. Why does non-adherence to treatment remain a leading cause of relapse in patients with bipolar disorder? Eur Neuropsychopharmacol. 2023;73:16–8.37119557
8. Horowitz MA Taylor D Tapering of SSRI treatment to mitigate withdrawal symptoms Lancet Psychiatry 2019 6 538 46 10.1016/S2215-0366(19)30032-X 30850328
Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:538–46.30850328
9. Renoir T Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved Front Pharm 2013 4 45 10.3389/fphar.2013.00045
Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharm. 2013;4:45.
10. Moncrieff J Crellin N Stansfeld J Cooper R Marston L Freemantle N Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial Lancet Psychiatry 2023 10 848 59 10.1016/S2215-0366(23)00258-4 37778356
Moncrieff J, Crellin N, Stansfeld J, Cooper R, Marston L, Freemantle N, et al. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial. Lancet Psychiatry. 2023;10:848–59.37778356
11. Borges S Chen YF Laughren TP Temple R Patel HD David PA Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration J Clin Psychiatry 2014 75 205 14 10.4088/JCP.13r08722 24717376
Borges S, Chen YF, Laughren TP, Temple R, Patel HD, David PA, et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry. 2014;75:205–14.24717376
12. Furukawa TA Cipriani A Barbui C Geddes JR Long-term treatment of depression with antidepressants: a systematic narrative review Can J Psychiatry 2007 52 545 52 10.1177/070674370705200902 17953158
Furukawa TA, Cipriani A, Barbui C, Geddes JR. Long-term treatment of depression with antidepressants: a systematic narrative review. Can J Psychiatry. 2007;52:545–52.17953158
13. Gueorguieva R Chekroud AM Krystal JH Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis Lancet Psychiatry 2017 4 230 7 10.1016/S2215-0366(17)30038-X 28189575
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. Lancet Psychiatry. 2017;4:230–7.28189575
14. Viguera AC Baldessarini RJ Friedberg J Discontinuing antidepressant treatment in major depression Harv Rev Psychiatry 1998 5 293 306 10.3109/10673229809003578 9559348
Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry. 1998;5:293–306.9559348
15. Kato M Hori H Inoue T Iga J Iwata M Inagaki T Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis Mol Psychiatry 2021 26 118 33 10.1038/s41380-020-0843-0 32704061
Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26:118–33.32704061
16. Lewis G Marston L Duffy L Freemantle N Gilbody S Hunter R Maintenance or discontinuation of antidepressants in primary care N Engl J Med 2021 385 1257 67 10.1056/NEJMoa2106356 34587384
Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021;385:1257–67.34587384
17. Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019 97 111 21 10.1016/j.addbeh.2018.08.027 30292574
Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav. 2019;97:111–21.30292574
18. Jauhar S Hayes J The war on antidepressants: what we can, and can’t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read Addict Behav 2019 97 122 5 10.1016/j.addbeh.2019.01.025 30732861
Jauhar S, Hayes J. The war on antidepressants: what we can, and can’t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav. 2019;97:122–5.30732861
19. Baldwin DS Montgomery SA Nil R Lader M Discontinuation symptoms in depression and anxiety disorders Int J Neuropsychopharmacol 2007 10 73 84 10.1017/S1461145705006358 16359583
Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10:73–84.16359583
20. Rosenbaum JF Fava M Hoog SL Ascroft RC Krebs WB Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial Biol Psychiatry 1998 44 77 87 10.1016/S0006-3223(98)00126-7 9646889
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77–87.9646889
21. Jauhar S Hayes J Goodwin GM Baldwin DS Cowen PJ Nutt DJ Antidepressants, withdrawal, and addiction; where are we now? J Psychopharmacol 2019 33 655 9 10.1177/0269881119845799 31111764
Jauhar S, Hayes J, Goodwin GM, Baldwin DS, Cowen PJ, Nutt DJ. Antidepressants, withdrawal, and addiction; where are we now? J Psychopharmacol. 2019;33:655–9.31111764
22. Horowitz MA Taylor D Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies BJPsych Adv 2022 28 297 311 10.1192/bja.2021.62
Horowitz MA, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Adv. 2022;28:297–311.
23. Meyer JH Wilson AA Sagrati S Hussey D Carella A Potter WZ Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study Am J Psychiatry 2004 161 826 35 10.1176/appi.ajp.161.5.826 15121647
Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–35.15121647
24. Fava GA Gatti A Belaise C Guidi J Offidani E Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review Psychother Psychosom 2015 84 72 81 10.1159/000370338 25721705
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84:72–81.25721705
25. Berwian IM Walter H Seifritz E Huys QJ Predicting relapse after antidepressant withdrawal—a systematic review Psychol Med 2017 47 426 37 10.1017/S0033291716002580 27786144
Berwian IM, Walter H, Seifritz E, Huys QJ. Predicting relapse after antidepressant withdrawal—a systematic review. Psychol Med. 2017;47:426–37.27786144
26. Figueroa CA Ruhe HG Koeter MW Spinhoven P Van der Does W Bockting CL Cognitive reactivity versus dysfunctional cognitions and the prediction of relapse in recurrent major depressive disorder J Clin Psychiatry 2015 76 e1306 12 10.4088/JCP.14m09268 26528654
Figueroa CA, Ruhe HG, Koeter MW, Spinhoven P, Van der Does W, Bockting CL, et al. Cognitive reactivity versus dysfunctional cognitions and the prediction of relapse in recurrent major depressive disorder. J Clin Psychiatry. 2015;76:e1306–12.26528654
27. de Klerk-Sluis JM Huijbers MJ Locke S Spijker J Spinhoven P Speckens AEM Factors associated with relapse and recurrence of major depressive disorder in patients starting mindfulness-based cognitive therapy Depress Anxiety 2022 39 113 22 10.1002/da.23220 34752681
de Klerk-Sluis JM, Huijbers MJ, Locke S, Spijker J, Spinhoven P, Speckens AEM, et al. Factors associated with relapse and recurrence of major depressive disorder in patients starting mindfulness-based cognitive therapy. Depress Anxiety. 2022;39:113–22.34752681
28. Berwian IM Wenzel JG Collins AGE Seifritz E Stephan KE Walter H Computational mechanisms of effort and reward decisions in patients with depression and their association with relapse after antidepressant discontinuation JAMA Psychiatry 2020 77 513 22 10.1001/jamapsychiatry.2019.4971 32074255
Berwian IM, Wenzel JG, Collins AGE, Seifritz E, Stephan KE, Walter H, et al. Computational mechanisms of effort and reward decisions in patients with depression and their association with relapse after antidepressant discontinuation. JAMA Psychiatry. 2020;77:513–22.32074255
29. Davidson JR Major depressive disorder treatment guidelines in America and Europe J Clin Psychiatry 2010 71 e04 10.4088/JCP.9058se1c.04gry 20371031
Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71:e04.20371031
30. Nutt DJ Davidson JR Gelenberg AJ Higuchi T Kanba S Karamustafalioglu O International consensus statement on major depressive disorder J Clin Psychiatry 2010 71 e08 10.4088/JCP.9058se1c.08gry 20371035
Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioglu O, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71:e08.20371035
31. Van Avendonk M van Weel-Baumgarten E van der Weele G Wiersma T Burgers JS Summary of the Dutch College of General Practitioners’ practice guideline ‘Depression’ Ned Tijdschr Geneeskd 2012 156 A5101 22992246
Van Avendonk M, van Weel-Baumgarten E, van der Weele G, Wiersma T, Burgers JS. Summary of the Dutch College of General Practitioners’ practice guideline ‘Depression’. Ned Tijdschr Geneeskd. 2012;156:A5101.22992246
32. Tint A Haddad PM Anderson IM The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study J Psychopharmacol 2008 22 330 2 10.1177/0269881107081550 18515448
Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008;22:330–2.18515448
33. Khan A Musgnung J Ramey T Messig M Buckley G Ninan PT Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d J Clin Psychopharmacol 2014 34 365 8 10.1097/JCP.0000000000000100 24717247
Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol. 2014;34:365–8.24717247
34. Gallagher JC Strzinek RA Cheng RF Ausmanas MK Astl D Seljan P The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause J Womens Health 2012 21 188 98 10.1089/jwh.2011.2764
Gallagher JC, Strzinek RA, Cheng RF, Ausmanas MK, Astl D, Seljan P. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. J Womens Health. 2012;21:188–98.
35. Ruhe HG Horikx A van Avendonk MJP Groeneweg BF Woutersen-Koch H Discontinuation of antidepressants T. Tapering of SSRI treatment to mitigate withdrawal symptoms Lancet Psychiatry 2019 6 561 2 10.1016/S2215-0366(19)30182-8 31230677
Ruhe HG, Horikx A, van Avendonk MJP, Groeneweg BF, Woutersen-Koch H. Discontinuation of antidepressants T. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:561–2.31230677
36. Papakostas GI Perlis RH Seifert C Fava M Antidepressant dose reduction and the risk of relapse in major depressive disorder Psychother Psychosom 2007 76 266 70 10.1159/000104702 17700046
Papakostas GI, Perlis RH, Seifert C, Fava M. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom. 2007;76:266–70.17700046
37. Breedvelt JJF Warren FC Segal Z Kuyken W Bockting CL Continuation of antidepressants vs sequential psychological interventions to prevent relapse in depression: an individual participant data meta-analysis JAMA Psychiatry 2021 78 868 75 10.1001/jamapsychiatry.2021.0823 34009273
Breedvelt JJF, Warren FC, Segal Z, Kuyken W, Bockting CL. Continuation of antidepressants vs sequential psychological interventions to prevent relapse in depression: an individual participant data meta-analysis. JAMA Psychiatry. 2021;78:868–75.34009273
38. Guidi J Fava GA Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder JAMA Psychiatry 2021 78 261 10.1001/jamapsychiatry.2020.3650 33237285
Guidi J, Fava GA. Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder. JAMA Psychiatry. 2021;78:261.33237285
39. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005 353 1209 23 10.1056/NEJMoa051688 16172203
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.16172203
40. Ostuzzi G Vita G Bertolini F Tedeschi F De Luca B Gastaldon C Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis Lancet Psychiatry 2022 9 614 24 10.1016/S2215-0366(22)00158-4 35753323
Ostuzzi G, Vita G, Bertolini F, Tedeschi F, De Luca B, Gastaldon C, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry. 2022;9:614–24.35753323
41. Taipale H Tanskanen A Correll CU Tiihonen J Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study Lancet Psychiatry 2022 9 271 9 10.1016/S2215-0366(22)00015-3 35182475
Taipale H, Tanskanen A, Correll CU, Tiihonen J. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry. 2022;9:271–9.35182475
42. Hojlund M Kemp AF Haddad PM Neill JC Correll CU Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials Lancet Psychiatry 2021 8 471 86 10.1016/S2215-0366(21)00078-X 34023019
Hojlund M, Kemp AF, Haddad PM, Neill JC, Correll CU. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry. 2021;8:471–86.34023019
43. Hui CLM Honer WG Lee EHM Chang WC Chan SKW Chen ESM Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial Lancet Psychiatry 2018 5 432 42 10.1016/S2215-0366(18)30090-7 29551618
Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018;5:432–42.29551618
44. Oh J Nam H Park S Chae JH Kim TS Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study Schizophr Res 2021 228 417 24 10.1016/j.schres.2021.01.006 33556675
Oh J, Nam H, Park S, Chae JH, Kim TS. Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study. Schizophr Res. 2021;228:417–24.33556675
45. Correll C Solmi M Croatto G Schneider L Rohani-Montez S Fairley L Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors World Psychiatry 2022 21 248 71 10.1002/wps.20994 35524619
Correll C, Solmi M, Croatto G, Schneider L, Rohani-Montez S, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21:248–71.35524619
46. Lähteenvuo M Tanskanen A Taipale H Hoti F Vattulainen P Vieta E Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder JAMA Psychiatry 2018 75 347 55 10.1001/jamapsychiatry.2017.4711 29490359
Lähteenvuo M, Tanskanen A, Taipale H, Hoti F, Vattulainen P, Vieta E, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry. 2018;75:347–55.29490359
47. Brandt L Bschor T Henssler J Muller M Hasan A Heinz A Antipsychotic withdrawal symptoms: a systematic review and meta-analysis Front Psychiatry 2020 11 569912 10.3389/fpsyt.2020.569912 33132934
Brandt L, Bschor T, Henssler J, Muller M, Hasan A, Heinz A, et al. Antipsychotic withdrawal symptoms: a systematic review and meta-analysis. Front Psychiatry. 2020;11:569912.33132934
48. Cosci F Chouinard G Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications Psychother Psychosom 2020 89 283 306 10.1159/000506868 32259826
Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89:283–306.32259826
49. Alvarez-Jimenez M Parker AG Hetrick SE McGorry PD Gleeson JF Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis Schizophr Bull 2011 37 619 30 10.1093/schbul/sbp129 19900962
Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37:619–30.19900962
50. Alvarez-Jimenez M O’Donoghue B Thompson A Gleeson JF Bendall S Gonzalez-Blanch C Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era CNS Drugs 2016 30 357 68 10.1007/s40263-016-0331-x 27106296
Alvarez-Jimenez M, O’Donoghue B, Thompson A, Gleeson JF, Bendall S, Gonzalez-Blanch C, et al. Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs. 2016;30:357–68.27106296
51. Bogers JPAM Hambarian G Walburgh Schmidt N Vermeulen JM de Haan L Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia: a systematic review and meta-analysis Schizophr Bull Open 2022 1 11 23
Bogers JPAM, Hambarian G, Walburgh Schmidt N, Vermeulen JM, de Haan L. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia: a systematic review and meta-analysis. Schizophr Bull Open. 2022;1:11–23.
52. Brandt L Ritter K Schneider-Thoma J Siafis S Montag C Ayrilmaz H Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis Lancet Psychiatry 2023 10 184 96 10.1016/S2215-0366(23)00008-1 36804071
Brandt L, Ritter K, Schneider-Thoma J, Siafis S, Montag C, Ayrilmaz H, et al. Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis. Lancet Psychiatry. 2023;10:184–96.36804071
53. Shimomura Y Kikuchi Y Suzuki T Uchida H Mimura M Takeuchi H Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms Schizophr Res 2020 215 8 16 10.1016/j.schres.2019.09.013 31784340
Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophr Res. 2020;215:8–16.31784340
54. Tiihonen J Tanskanen A Taipale H 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia Am J Psychiatry 2018 175 765 73 10.1176/appi.ajp.2018.17091001 29621900
Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175:765–73.29621900
55. Luykx JJ Stam N Tanskanen A Tiihonen J Taipale H In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine Br J Psychiatry 2020 217 498 505 10.1192/bjp.2019.267 31910911
Luykx JJ, Stam N, Tanskanen A, Tiihonen J, Taipale H. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. Br J Psychiatry. 2020;217:498–505.31910911
56. Horowitz MA Jauhar S Natesan S Murray RM Taylor D A method for tapering antipsychotic treatment that may minimize the risk of relapse Schizophr Bull 2021 47 1116 29 10.1093/schbul/sbab017 33754644
Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull. 2021;47:1116–29.33754644
57. Brandt L Schneider-Thoma J Siafis S Efthimiou O Bermpohl F Loncar L Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis Lancet Psychiatry 2022 9 232 42 10.1016/S2215-0366(22)00014-1 35183280
Brandt L, Schneider-Thoma J, Siafis S, Efthimiou O, Bermpohl F, Loncar L, et al. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. Lancet Psychiatry. 2022;9:232–42.35183280
58. Tani H Takasu S Uchida H Suzuki T Mimura M Takeuchi H Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials Neuropsychopharmacology 2020 45 887 901 10.1038/s41386-019-0573-7 31770770
Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Neuropsychopharmacology. 2020;45:887–901.31770770
59. Leucht S Bauer S Siafis S Hamza T Wu H Schneider-Thoma J Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis JAMA Psychiatry 2021 78 1238 48 10.1001/jamapsychiatry.2021.2130 34406325
Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis. JAMA Psychiatry. 2021;78:1238–48.34406325
60. Wunderink L Nieboer RM Wiersma D Sytema S Nienhuis FJ Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial JAMA Psychiatry 2013 70 913 20 10.1001/jamapsychiatry.2013.19 23824214
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70:913–20.23824214
61. Omachi Y Sumiyoshi T Dose reduction/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes Front Psychiatry 2018 9 447 10.3389/fpsyt.2018.00447 30294286
Omachi Y, Sumiyoshi T. Dose reduction/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes. Front Psychiatry. 2018;9:447.30294286
62. Weller A Gleeson J Alvarez-Jimenez M McGorry P Nelson B Allott K Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: study protocol Early Inter Psychiatry 2019 13 1345 56 10.1111/eip.12769
Weller A, Gleeson J, Alvarez-Jimenez M, McGorry P, Nelson B, Allott K, et al. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: study protocol. Early Inter Psychiatry. 2019;13:1345–56.
63. Begemann MJH Thompson IA Veling W Gangadin SS Geraets CNW van‘t Hag E To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial Trials 2020 21 147 10.1186/s13063-019-3822-5 32033579
Begemann MJH, Thompson IA, Veling W, Gangadin SS, Geraets CNW, van‘t Hag E, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21:147.32033579
64. Liu CC Hsieh MH Chien YL Liu CM Lin YT Hwang TJ Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design Early Inter Psychiatry 2021 16 178 85 10.1111/eip.13144
Liu CC, Hsieh MH, Chien YL, Liu CM, Lin YT, Hwang TJ, et al. Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design. Early Inter Psychiatry. 2021;16:178–85.
65. Remington G Kapur S Antipsychotic dosing: how much but also how often? Schizophr Bull 2010 36 900 3 10.1093/schbul/sbq083 20650931
Remington G, Kapur S. Antipsychotic dosing: how much but also how often? Schizophr Bull. 2010;36:900–3.20650931
66. Gaebel W Intermittent medication—an alternative? Acta Psychiatr Scand Suppl 1994 382 33 8 10.1111/j.1600-0447.1994.tb05863.x 7916527
Gaebel W. Intermittent medication—an alternative? Acta Psychiatr Scand Suppl. 1994;382:33–8.7916527
67. Horowitz MA Moncrieff J de Haan L Bogers J Gangadin SS Kikkert M Tapering antipsychotic medication: practical considerations Psychol Med 2022 52 32 35 10.1017/S0033291721003299 34542027
Horowitz MA, Moncrieff J, de Haan L, Bogers J, Gangadin SS, Kikkert M, et al. Tapering antipsychotic medication: practical considerations. Psychol Med. 2022;52:32–35.34542027
68. Qureshi MM Young AH Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder Ther Adv Psychopharmacol 2021 11 20451253211000612 10.1177/20451253211000612 33796268
Qureshi MM, Young AH. Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder. Ther Adv Psychopharmacol. 2021;11:20451253211000612.33796268
69. Murru A Colom F Nivoli A Pacchiarotti I Valenti M Vieta E When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations Eur Psychiatry 2011 26 183 6 10.1016/j.eurpsy.2010.09.012 21288696
Murru A, Colom F, Nivoli A, Pacchiarotti I, Valenti M, Vieta E. When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. Eur Psychiatry. 2011;26:183–6.21288696
70. Biel MG Peselow E Mulcare L Case BG Fieve R Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study Bipolar Disord 2007 9 435 42 10.1111/j.1399-5618.2007.00389.x 17680913
Biel MG, Peselow E, Mulcare L, Case BG, Fieve R. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord. 2007;9:435–42.17680913
71. Baldessarini RJ Tondo L Hennen J Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders J Clin Psychiatry 1999 60 77 84 10073392
Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999;60:77–84.10073392
72. Kishi T Matsuda Y Sakuma K Okuya M Mishima K Iwata N Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis Psychol Med 2021 51 2721 9 10.1017/S0033291720003505 33046156
Kishi T, Matsuda Y, Sakuma K, Okuya M, Mishima K, Iwata N. Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis. Psychol Med. 2021;51:2721–9.33046156
73. Gutwinski S Fierley L Schreiter S Bermpohl F Heinz A Henssler J Lithium withdrawal symptoms—a systematic review Psychiatr Prax 2021 48 341 50 10.1055/a-1481-1953 34015856
Gutwinski S, Fierley L, Schreiter S, Bermpohl F, Heinz A, Henssler J. Lithium withdrawal symptoms—a systematic review. Psychiatr Prax. 2021;48:341–50.34015856
74. Faedda GL Tondo L Baldessarini RJ Suppes T Tohen M Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders Arch Gen Psychiatry 1993 50 448 55 10.1001/archpsyc.1993.01820180046005 8498879
Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993;50:448–55.8498879
75. de Vries C van Bergen A Regeer EJ Benthem E Kupka RW Boks MP The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness Bipolar Disord 2013 15 645 9 10.1111/bdi.12105 23911110
de Vries C, van Bergen A, Regeer EJ, Benthem E, Kupka RW, Boks MP. The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness. Bipolar Disord. 2013;15:645–9.23911110
76. Yatham LN Kennedy SH Parikh SV Schaffer A Bond DJ Frey BN Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder Bipolar Disord 2018 20 97 170 10.1111/bdi.12609 29536616
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.29536616
77. Tohen M Frank E Bowden CL Colom F Ghaemi SN Yatham LN The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders Bipolar Disord 2009 11 453 73 10.1111/j.1399-5618.2009.00726.x 19624385
Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11:453–73.19624385
78. Taylor D, Barnes T, Young A. Maudsley prescribing guidelines in psychiatry. 14th ed. New York, NY: Wiley Blackwell; 2021.
79. Holm M Tanskanen A Lähteenvuo M Tiihonen J Taipale H Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder Eur Neurpscyhopharmacol 2022 61 36 42 10.1016/j.euroneuro.2022.05.012
Holm M, Tanskanen A, Lähteenvuo M, Tiihonen J, Taipale H. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder. Eur Neurpscyhopharmacol. 2022;61:36–42.
80. Nolen WA Licht RW Young AH Malhi GS Tohen M Vieta E What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium Bipolar Disord 2019 21 394 409 10.1111/bdi.12805 31112628
Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta E, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord. 2019;21:394–409.31112628
81. Ribeiro PRS Schlindwein AD Benzodiazepine deprescription strategies in chronic users: a systematic review Fam Pr 2021 38 684 93 10.1093/fampra/cmab017
Ribeiro PRS, Schlindwein AD. Benzodiazepine deprescription strategies in chronic users: a systematic review. Fam Pr. 2021;38:684–93.
82. Reeve E Ong M Wu A Jansen J Petrovic M Gnjidic D A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people Eur J Clin Pharm 2017 73 927 35 10.1007/s00228-017-2257-8
Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharm. 2017;73:927–35.
83. Voshaar RC Couvee JE van Balkom AJ Mulder PG Zitman FG Strategies for discontinuing long-term benzodiazepine use: meta-analysis Br J Psychiatry 2006 189 213 20 10.1192/bjp.189.3.213 16946355
Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213–20.16946355
84. Jobert A Laforgue EJ Grall-Bronnec M Rousselet M Pere M Jolliet P Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Eur J Clin Pharm 2021 77 171 7 10.1007/s00228-020-03007-7
Jobert A, Laforgue EJ, Grall-Bronnec M, Rousselet M, Pere M, Jolliet P, et al. Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Eur J Clin Pharm. 2021;77:171–7.
85. Inoue Y Takaesu Y Koebis M Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study BMC Psychiatry 2021 21 193 10.1186/s12888-021-03196-0 33853571
Inoue Y, Takaesu Y, Koebis M. Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study. BMC Psychiatry. 2021;21:193.33853571
86. Lader M Kyriacou A Withdrawing benzodiazepines in patients with anxiety disorders Curr Psychiatry Rep 2016 18 8 10.1007/s11920-015-0642-5 26733324
Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep. 2016;18:8.26733324
87. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015(5):CD009652.
88. Petursson H The benzodiazepine withdrawal syndrome Addiction 1994 89 1455 9 10.1111/j.1360-0443.1994.tb03743.x 7841856
Petursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89:1455–9.7841856
89. Basinska-Szafranska A Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking Eur J Clin Pharm 2022 78 101 10 10.1007/s00228-021-03205-x
Basinska-Szafranska A. Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking. Eur J Clin Pharm. 2022;78:101–10.
90. Rickels K Schweizer E Case WG Greenblatt DJ Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation Arch Gen Psychiatry 1990 47 899 907 10.1001/archpsyc.1990.01810220015002 2222129
Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899–907.2222129
91. Schweizer E Rickels K Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management Acta Psychiatr Scand Suppl 1998 393 95 101 10.1111/j.1600-0447.1998.tb05973.x 9777054
Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl. 1998;393:95–101.9777054
92. Rasmussen AF Poulsen SS Oldenburg LIK Vermehren C The barriers and facilitators of different stakeholders when deprescribing benzodiazepine receptor agonists in older patients—a systematic review Metabolites 2021 11 254 10.3390/metabo11040254 33923956
Rasmussen AF, Poulsen SS, Oldenburg LIK, Vermehren C. The barriers and facilitators of different stakeholders when deprescribing benzodiazepine receptor agonists in older patients—a systematic review. Metabolites. 2021;11:254.33923956
93. Baandrup L Ebdrup BH Rasmussen JO Lindschou J Gluud C Glenthoj BY Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users Cochrane Database Syst Rev 2018 3 CD011481 29543325
Baandrup L, Ebdrup BH, Rasmussen JO, Lindschou J, Gluud C, Glenthoj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3:CD011481.29543325
94. Vinkers CH Olivier B Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharm Sci 2012 2012 416864
Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharm Sci. 2012;2012:416864.
95. Lader M Tylee A Donoghue J Withdrawing benzodiazepines in primary care CNS Drugs 2009 23 19 34 10.2165/0023210-200923010-00002 19062773
Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19–34.19062773
96. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health; 2017.
97. Brouillet E Chavoix C Bottlaender M Khalili-Varasteh M Hantraye P Fournier D In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates Brain Res 1991 557 167 76 10.1016/0006-8993(91)90131-E 1660750
Brouillet E, Chavoix C, Bottlaender M, Khalili-Varasteh M, Hantraye P, Fournier D, et al. In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. Brain Res. 1991;557:167–76.1660750
98. Lingford-Hughes AR Welch S Peters L Nutt DJ British Association for Psychopharmacology ERG. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP J Psychopharmacol 2012 26 899 952 10.1177/0269881112444324 22628390
Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. British Association for Psychopharmacology ERG. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26:899–952.22628390
99. Soyka M Treatment of benzodiazepine dependence N Engl J Med 2017 376 1147 57 10.1056/NEJMra1611832 28328330
Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376:1147–57.28328330
100. Takaesu Y Utsumi T Okajima I Shimura A Kotorii N Kuriyama K Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis Sleep Med Rev 2019 48 101214 10.1016/j.smrv.2019.101214 31648145
Takaesu Y, Utsumi T, Okajima I, Shimura A, Kotorii N, Kuriyama K, et al. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2019;48:101214.31648145
101. Gould RL Coulson MC Patel N Highton-Williamson E Howard RJ Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials Br J Psychiatry 2014 204 98 107 10.1192/bjp.bp.113.126003 24493654
Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204:98–107.24493654
102. Lynch T Ryan C Hughes CM Presseau J van Allen ZM Bradley CP Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis Addiction 2020 115 1618 39 10.1111/add.14981 31985127
Lynch T, Ryan C, Hughes CM, Presseau J, van Allen ZM, Bradley CP, et al. Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis. Addiction. 2020;115:1618–39.31985127
103. Mugunthan K McGuire T Glasziou P Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis Br J Gen Pr 2011 61 e573 8 10.3399/bjgp11X593857
Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pr. 2011;61:e573–8.
104. Parr JM Kavanagh DJ Cahill L Mitchell G Mc DYR Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis Addiction 2009 104 13 24 10.1111/j.1360-0443.2008.02364.x 18983627
Parr JM, Kavanagh DJ, Cahill L, Mitchell G, Mc DYR. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104:13–24.18983627
105. Gallo AT Hulse G Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data J Psychopharmacol 2021 35 211 20 10.1177/0269881120981390 33426982
Gallo AT, Hulse G. Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. J Psychopharmacol. 2021;35:211–20.33426982
106. MacDonald T Gallo AT Basso-Hulse G Hulse GK Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: a description of 26 participants Drug Alcohol Depend 2022 237 109517 10.1016/j.drugalcdep.2022.109517 35688053
MacDonald T, Gallo AT, Basso-Hulse G, Hulse GK. Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: a description of 26 participants. Drug Alcohol Depend. 2022;237:109517.35688053
107. Manchikanti L Vallejo R Manchikanti KN Benyamin RM Datta S Christo PJ Effectiveness of long-term opioid therapy for chronic non-cancer pain Pain Physician 2011 14 E133 56 10.36076/ppj.2011/14/E133 21412378
Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician. 2011;14:E133–56.21412378
108. Abdel Shaheed C Maher CG Williams KA Day R McLachlan AJ Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis JAMA Intern Med 2016 176 958 68 10.1001/jamainternmed.2016.1251 27213267
Abdel Shaheed C, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016;176:958–68.27213267
109. Busse JW Wang L Kamaleldin M Craigie S Riva JJ Montoya L Opioids for chronic noncancer pain: a systematic review and meta-analysis JAMA 2018 320 2448 60 10.1001/jama.2018.18472 30561481
Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320:2448–60.30561481
110. van Rijswijk SM van Beek M Schoof GM Schene AH Steegers M Schellekens AF Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: a systematic review Gen Hosp Psychiatry 2019 59 37 50 10.1016/j.genhosppsych.2019.04.008 31141759
van Rijswijk SM, van Beek M, Schoof GM, Schene AH, Steegers M, Schellekens AF. Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: a systematic review. Gen Hosp Psychiatry. 2019;59:37–50.31141759
111. Griffin ML Bennett HE Fitzmaurice GM Hill KP Provost SE Weiss RD Health-related quality of life among prescription opioid-dependent patients: results from a multi-site study Am J Addict 2015 24 308 14 10.1111/ajad.12188 25808055
Griffin ML, Bennett HE, Fitzmaurice GM, Hill KP, Provost SE, Weiss RD. Health-related quality of life among prescription opioid-dependent patients: results from a multi-site study. Am J Addict. 2015;24:308–14.25808055
112. Higgins C Smith BH Matthews K Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis Br J Anaesth 2018 120 1335 44 10.1016/j.bja.2018.03.009 29793599
Higgins C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. Br J Anaesth. 2018;120:1335–44.29793599
113. Smyth BP Barry J Keenan E Ducray K Lapse and relapse following inpatient treatment of opiate dependence Ir Med J 2010 103 176 9 20669601
Smyth BP, Barry J, Keenan E, Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J. 2010;103:176–9.20669601
114. Huffman KL Sweis GW Gase A Scheman J Covington EC Opioid use 12 months following interdisciplinary pain rehabilitation with weaning Pain Med 2013 14 1908 17 10.1111/pme.12201 23915328
Huffman KL, Sweis GW, Gase A, Scheman J, Covington EC. Opioid use 12 months following interdisciplinary pain rehabilitation with weaning. Pain Med. 2013;14:1908–17.23915328
115. Bruneau J Ahamad K Goyer M Poulin G Selby P Fischer B Management of opioid use disorders: a national clinical practice guideline CMAJ 2018 190 E247 57 10.1503/cmaj.170958 29507156
Bruneau J, Ahamad K, Goyer M, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190:E247–57.29507156
116. Frank JW Lovejoy TI Becker WC Morasco BJ Koenig CJ Hoffecker L Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review Ann Intern Med 2017 167 181 91 10.7326/M17-0598 28715848
Frank JW, Lovejoy TI, Becker WC, Morasco BJ, Koenig CJ, Hoffecker L, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med. 2017;167:181–91.28715848
117. Tsui JI Lira MC Cheng DM Winter MR Alford DP Liebschutz JM Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy Drug Alcohol Depend 2016 166 26 31 10.1016/j.drugalcdep.2016.06.024 27422763
Tsui JI, Lira MC, Cheng DM, Winter MR, Alford DP, Liebschutz JM, et al. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. Drug Alcohol Depend. 2016;166:26–31.27422763
118. Duceppe MA Perreault MM Frenette AJ Burry LD Rico P Lavoie A Frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and benzodiazepines in critically Ill neonates, children and adults: a systematic review of clinical studies J Clin Pharm Ther 2019 44 148 56 10.1111/jcpt.12787 30569508
Duceppe MA, Perreault MM, Frenette AJ, Burry LD, Rico P, Lavoie A, et al. Frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and benzodiazepines in critically Ill neonates, children and adults: a systematic review of clinical studies. J Clin Pharm Ther. 2019;44:148–56.30569508
119. Bienek N Maier C Kaisler M Michel-Lauter B Schwarzer A Meyer-Frießem CH Intensity of withdrawal symptoms during opioid taper in patients with chronic pain-individualized or fixed starting dosage? Pain Med 2019 20 2438 49 10.1093/pm/pny320 30806672
Bienek N, Maier C, Kaisler M, Michel-Lauter B, Schwarzer A, Meyer-Frießem CH. Intensity of withdrawal symptoms during opioid taper in patients with chronic pain-individualized or fixed starting dosage? Pain Med. 2019;20:2438–49.30806672
120. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
121. Kosten TR Baxter LE Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment Am J Addict 2019 28 55 62 10.1111/ajad.12862 30701615
Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28:55–62.30701615
122. Mark TL Parish W Opioid medication discontinuation and risk of adverse opioid-related health care events J Subst Abus Treat 2019 103 58 63 10.1016/j.jsat.2019.05.001
Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abus Treat. 2019;103:58–63.
123. Mackey K Anderson J Bourne D Chen E Peterson K Benefits and harms of long-term opioid dose reduction or discontinuation in patients with chronic pain: a rapid review J Gen Intern Med 2020 35 935 44 10.1007/s11606-020-06253-8 33145689
Mackey K, Anderson J, Bourne D, Chen E, Peterson K. Benefits and harms of long-term opioid dose reduction or discontinuation in patients with chronic pain: a rapid review. J Gen Intern Med. 2020;35:935–44.33145689
124. Demidenko MI Dobscha SK Morasco BJ Meath THA Ilgen MA Lovejoy TI Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users Gen Hosp Psychiatry 2017 47 29 35 10.1016/j.genhosppsych.2017.04.011 28807135
Demidenko MI, Dobscha SK, Morasco BJ, Meath THA, Ilgen MA, Lovejoy TI. Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users. Gen Hosp Psychiatry. 2017;47:29–35.28807135
125. Quinn PD Chang Z Bair MJ Rickert ME Gibbons RD Kroenke K Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy Pain 2021 163 e588 95 10.1097/j.pain.0000000000002415
Quinn PD, Chang Z, Bair MJ, Rickert ME, Gibbons RD, Kroenke K, et al. Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy. Pain. 2021;163:e588–95.
126. Binswanger IA Glanz JM Faul M Shoup JA Quintana LM Lyden J The association between opioid discontinuation and heroin use: a nested case-control study Drug Alcohol Depend 2020 217 108248 10.1016/j.drugalcdep.2020.108248 32927194
Binswanger IA, Glanz JM, Faul M, Shoup JA, Quintana LM, Lyden J, et al. The association between opioid discontinuation and heroin use: a nested case-control study. Drug Alcohol Depend. 2020;217:108248.32927194
127. Pergolizzi JV Jr Rosenblatt M Mariano DJ Bisney J Tapering opioid therapy: clinical strategies Pain Manag 2018 8 409 13 10.2217/pmt-2018-0040 30394191
Pergolizzi JV Jr, Rosenblatt M, Mariano DJ, Bisney J. Tapering opioid therapy: clinical strategies. Pain Manag. 2018;8:409–13.30394191
128. Davis MP Digwood G Mehta Z McPherson ML Tapering opioids: a comprehensive qualitative review Ann Palliat Med 2020 9 586 610 10.21037/apm.2019.12.10 32008341
Davis MP, Digwood G, Mehta Z, McPherson ML. Tapering opioids: a comprehensive qualitative review. Ann Palliat Med. 2020;9:586–610.32008341
129. Minegishi T Garrido MM Stein M Oliva EM Frakt AB Opioid discontinuation among patients receiving high-dose long-term opioid therapy in the veterans health administration J Gen Intern Med 2020 35 903 9 10.1007/s11606-020-06252-9 33145683
Minegishi T, Garrido MM, Stein M, Oliva EM, Frakt AB. Opioid discontinuation among patients receiving high-dose long-term opioid therapy in the veterans health administration. J Gen Intern Med. 2020;35:903–9.33145683
130. Campbell G Bruno R Darke S Degenhardt L Associations of borderline personality with pain, problems with medications and suicidality in a community sample of chronic non-cancer pain patients prescribed opioids for pain Gen Hosp Psychiatry 2015 37 434 40 10.1016/j.genhosppsych.2015.05.004 26112358
Campbell G, Bruno R, Darke S, Degenhardt L. Associations of borderline personality with pain, problems with medications and suicidality in a community sample of chronic non-cancer pain patients prescribed opioids for pain. Gen Hosp Psychiatry. 2015;37:434–40.26112358
131. Scherrer JF Salas J Sullivan MD Ahmedani BK Copeland LA Bucholz KK Impact of adherence to antidepressants on long-term prescription opioid use cessation Br J Psychiatry 2018 212 103 11 10.1192/bjp.2017.25 29436331
Scherrer JF, Salas J, Sullivan MD, Ahmedani BK, Copeland LA, Bucholz KK, et al. Impact of adherence to antidepressants on long-term prescription opioid use cessation. Br J Psychiatry. 2018;212:103–11.29436331
132. Mercadante S Arcuri E Santoni A Opioid-induced tolerance and hyperalgesia CNS Drugs 2019 33 943 55 10.1007/s40263-019-00660-0 31578704
Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33:943–55.31578704
133. US Department of Health and Human Services. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. 2019. https://www.drugabuse.gov/nidamed-medical-health-professionals/opioid-crisis-pain-management/hhs-guide-clinicians-appropriate-dosage-reduction-or-discontinuation-long-term-opioid.
134. US Department of Veterans Affairs. Pain management opioid taper decision tool; a VA clinician’s Guide. 2016. http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp.
135. Kaye AD Jones MR Kaye AM Ripoll JG Galan V Beakley BD Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1 Pain Physician 2017 20 S93 109 10.36076/ppj.2017.s109 28226333
Kaye AD, Jones MR, Kaye AM, Ripoll JG, Galan V, Beakley BD, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Physician. 2017;20:S93–109.28226333
136. Noble M Treadwell JR Tregear SJ Coates VH Wiffen PJ Akafomo C Long-term opioid management for chronic noncancer pain Cochrane Database Syst Rev 2010 2010 Cd006605 20091598
Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;2010:Cd006605.20091598
137. Dijkstra B, Van Oort M, Schellekens A, De Haan H, De Jong C. Dutch guidelines on detoxification of psychoactive substances. Amsterfoort: Resultaten Scoren; 2017.
138. Tripp CC, Rak E, Burker E. A review of effective treatments for patients with co-occurring chronic pain and opioid addiction. VISTAS Online. 2017.
139. Lohr WD Wanta JW Baker M Grudnikoff E Morgan W Chhabra D Intentional discontinuation of psychostimulants used to treat ADHD in youth: a review and analysis Front Psychiatry 2021 12 642798 10.3389/fpsyt.2021.642798 33959050
Lohr WD, Wanta JW, Baker M, Grudnikoff E, Morgan W, Chhabra D, et al. Intentional discontinuation of psychostimulants used to treat ADHD in youth: a review and analysis. Front Psychiatry. 2021;12:642798.33959050
140. Zeiner P Do the beneficial effects of extended methylphenidate treatment in boys with attention-deficit hyperactivity disorder dissipate rapidly during placebo treatment? Nord J Psychiatry 1999 53 55 60 10.1080/080394899426738
Zeiner P. Do the beneficial effects of extended methylphenidate treatment in boys with attention-deficit hyperactivity disorder dissipate rapidly during placebo treatment? Nord J Psychiatry. 1999;53:55–60.
141. Arnold LE Lindsay RL Conners CK Wigal SB Levine AJ Johnson DE A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder J Child Adolesc Psychopharmacol 2004 14 542 54 10.1089/cap.2004.14.542 15662146
Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2004;14:542–54.15662146
142. Coghill DR Banaschewski T Lecendreux M Johnson M Zuddas A Anderson CS Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design J Am Acad Child Adolesc Psychiatry 2014 53 647 e51 10.1016/j.jaac.2014.01.017 24839883
Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53:647–e51.24839883
143. Howland RH Potential adverse effects of discontinuing psychotropic drugs J Psychosoc Nurs Ment health Serv 2010 48 11 4 20795589
Howland RH. Potential adverse effects of discontinuing psychotropic drugs. J Psychosoc Nurs Ment health Serv. 2010;48:11–4.20795589
144. Tsujii N Okada T Usami M Kuwabara H Fujita J Negoro H Effect of continuing and discontinuing medications on quality of life after symptomatic remission in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis J Clin Psychiatry 2020 81 19r13015 10.4088/JCP.19r13015 32237294
Tsujii N, Okada T, Usami M, Kuwabara H, Fujita J, Negoro H, et al. Effect of continuing and discontinuing medications on quality of life after symptomatic remission in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2020;81:19r13015.32237294
145. National Guideline Center. Attention deficit hyperactivity disorder: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2019.
146. Pliszka S Issues AWGoQ. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2007 46 894 921 10.1097/chi.0b013e318054e724 17581453
Pliszka S. Issues AWGoQ. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.17581453
147. Faraone SV Banaschewski T Coghill D Zheng Y Biederman J Bellgrove MA The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder Neurosci Biobehav Rev 2021 128 789 818 10.1016/j.neubiorev.2021.01.022 33549739
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818.33549739
148. Sandler AD Glesne CE Bodfish JW Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr 2010 31 369 75 10.1097/DBP.0b013e3181e121ed 20495473
Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31:369–75.20495473
149. National Guideline Centre (UK). Withdrawal from pharmacological treatment and drug holidays: attention deficit hyperactivity disorder: diagnosis and management: evidence review I. London: National Institute for Health and Care Excellence (NICE); 2018.
150. World Health Organization. Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings. Geneva: World Health Organization; 2009.
151. Vinkers CH Ruhe HG Penninx BW Antidepressant discontinuation: in need of scientific evidence J Clin Psychopharmacol 2021 41 512 5 10.1097/JCP.0000000000001460 34412108
Vinkers CH, Ruhe HG, Penninx BW. Antidepressant discontinuation: in need of scientific evidence. J Clin Psychopharmacol. 2021;41:512–5.34412108
152. Wentink C Huijbers MJ Lucassen PL van der Gouw A Kramers C Spijker J Enhancing shared decision making about discontinuation of antidepressant medication: a concept-mapping study in primary and secondary mental health care Br J Gen Pr 2019 69 e777 85 10.3399/bjgp19X706001
Wentink C, Huijbers MJ, Lucassen PL, van der Gouw A, Kramers C, Spijker J, et al. Enhancing shared decision making about discontinuation of antidepressant medication: a concept-mapping study in primary and secondary mental health care. Br J Gen Pr. 2019;69:e777–85.
153. Desai M Park T Deprescribing practices in Canada: a scoping review Can Pharm J 2022 155 249 57 10.1177/17151635221114114
Desai M, Park T. Deprescribing practices in Canada: a scoping review. Can Pharm J. 2022;155:249–57.
154. Grootens K Verwijmeren D A shared decision journey to bridge the gap between treatment recommendation and low adherence? Eur Neuropsychopharmacol 2023 69 77 8 10.1016/j.euroneuro.2023.01.007 36780818
Grootens K, Verwijmeren D. A shared decision journey to bridge the gap between treatment recommendation and low adherence? Eur Neuropsychopharmacol. 2023;69:77–8.36780818
155. Horowitz M Taylor D How to reduce and stop psychiatric medication Eur Neuropsychopharmacol 2022 55 4 7 10.1016/j.euroneuro.2021.10.001 34688998
Horowitz M, Taylor D. How to reduce and stop psychiatric medication. Eur Neuropsychopharmacol. 2022;55:4–7.34688998
156. Quilichini JB Revet A Garcia P Bouquie R Hamard J Yrondi A Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: a real-world study using the WHO pharmacovigilance database J Affect Disord 2022 297 189 93 10.1016/j.jad.2021.10.041 34699855
Quilichini JB, Revet A, Garcia P, Bouquie R, Hamard J, Yrondi A, et al. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: a real-world study using the WHO pharmacovigilance database. J Affect Disord. 2022;297:189–93.34699855
157. Kuyken W Hayes R Barrett B Byng R Dalgleish T Kessler D Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial Lancet 2015 386 63 73 10.1016/S0140-6736(14)62222-4 25907157
Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet. 2015;386:63–73.25907157
158. Uhlenhuth EH Balter MB Ban TA Yang K International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders J Clin Psychopharmacol 1999 19 23S 9S 10.1097/00004714-199912002-00005 10587281
Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J Clin Psychopharmacol. 1999;19:23S–9S.10587281
159. Gowing L Farrell M Ali R White JM Alpha(2)-adrenergic agonists for the management of opioid withdrawal Cochrane Database Syst Rev 2016 2016 CD002024 27140827
Gowing L, Farrell M, Ali R, White JM. Alpha(2)-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;2016:CD002024.27140827
